Metastatic Spermatocytic Seminoma

Schoborg, Thomas W.; Whittaker, J. A.; Lewis, Charles

doi:10.1016/s0022-5347(17)55636-0

Cited by 12 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1980, Schoborg et al 25 reported an additional case of SS associated with metastases and fatal outcome 2 years after the initial presentation. The patient apparently died from the side effects of chemotherapy.…”

Section: Metastases In Spermatocytic Seminomamentioning

confidence: 99%

Review Article: Spermatocytic Seminoma: Review of the Literature and Description of a New Case of the Anaplastic Variant

et al. 2011

View full text Add to dashboard Cite

The aims of this paper were to review the literature of Spermatocytic Seminoma (SS) updating its clinico-pathological features and to present a new case of the exceptionally rare variant of this tumor known as anaplastic which only five cases have been reported. Many studies have confirmed that SS is a distinct neoplasm both clinically and pathologically from classical Seminoma and it differs from the latter especially in regard to behavior, characterized by an almost complete inability to metastasize with only very few convincing examples described with metastatic behavior. There is general agreement that orchidectomy is sufficient therapy for SS and that surveillance following surgery is the preferred management option. Surprisingly, the presence of an anaplastic component does not seem to impact on this excellent prognosis. Very different is the case of sarcomatous transformation, for which further therapy after orchiectomy is advisable.

show abstract

Section: Metastases In Spermatocytic Seminomamentioning

confidence: 99%

Review Article: Spermatocytic Seminoma: Review of the Literature and Description of a New Case of the Anaplastic Variant

et al. 2011

View full text Add to dashboard Cite

show abstract

“…To further expand those recommendations, we set-up a multicenter registry and invite other centers to contribute their experiences in patients with spermatocytic tumors. Bohm et al (1993) After adjuvant and tumor negative modified template RPLND, retroperitoneal recurrence treated with neoadjuvant chemotherapy (BEP + PVB) followed by cytoreductive RPLND N/A Matoška et al (1988) RPLND + radiotherapy (38.4Gray) to the retroperitoneum, followed by PVB Died 25 months after orchiectomy during chemotherapy because of sepsis Mikuz et al (2014) BEP PEI + RPLND PD after 2 months PD, alive with metastases in liver and kidney Steiner et al (2006) Orchiectomy + 2 cycles adjuvant Carboplatin RPLND + 2xBEP PD after 10 months NED after 3 years follow-up Choi et al (2017) Radiotherapy to brain metastases PD Schoborg et al (1980) Radiotherapy to para-aortic and inguinal LNDs (2600 rad)…”

Section: Discussionmentioning

confidence: 99%

A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis

Grogg

Schneider

Bode

et al. 2019

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction Because spermatocytic tumors of the testis are rare, only limited evidence exists regarding the malignant potential and the optimal management of localized and metastatic disease. Materials and methods We performed a systematic review through MEDLINE, EMBASE, Scopus, Cochrane Database of Systematic Reviews and Web of Science to identify reports including patients with testicular spermatocytic tumors. Results From originally 7863 studies, we extracted data of 146 patients of which 99% were treated with radical orchiectomy. Metastases in patients with initially localised disease were diagnosed in 7% of patients and detected after a median follow-up of 5.5 months (range 2-21 months). Patients with aggressive histology (sarcoma or anaplastic subtype) were more likely to have metastatic disease (6/124 (5%) vs 9/22 (41%), p < 0.001). Patients with metastatic disease had larger primary tumors (92.5 vs 67.5 mm, p = 0.05). Life expectancy in patients with metastatic disease ranged from 1 to 25 months. Conclusion The published literature does neither support the use of testis sparing surgery nor adjuvant therapy. Patients with aggressive variants or larger tumors were more likely to have metastases and develop recurrences within the first few years. Patients with metastatic disease have a limited life expectancy and metastatic spermatocytic tumors are not as responsive to chemotherapy as germ cell cancers.

show abstract

“…Schoborg [19] beschrieb 1980 einen Patienten, welcher bei Erstdiagnose in der Lymphographie vergrößerte paraaortale Lymphknoten aufwies und 6 Monate später axilläre Lymphknotenmetastasen entwickelte. Bei letzteren erfolgte eine histologische Diagnosesicherung mittels Nadelaspiratonsbiopsie.…”

Section: Krankheitsverlauf Und Therapieunclassified

Das spermatozytäre Seminom

Bremer¹,

Bense²,

Güner³

et al. 2002

Der Urologe A

View full text Add to dashboard Cite

The spermatocytic seminoma is a distinct testicular neoplasm with a low tendency to metastasize. Two own cases with the diagnosis of a spermatocytic seminoma are presented. A third patient is described, where the initial diagnosis of a spermatocytic seminoma was retrospectively changed to classical seminoma after developing retroperitoneal relapse during surveillance. A literature review revealed distinct histopathological characteristics and a remarkably good prognosis for spermatocytic seminoma. With only one case of relapse confirmed in the literature, in these patients postoperative treatment can safely be omitted in favor of surveillance. In case of spermatocytic seminoma diagnosis should be confirmed by a second pathologist.

show abstract

Metastatic Spermatocytic Seminoma

Cited by 12 publications

References 5 publications

Review Article: Spermatocytic Seminoma: Review of the Literature and Description of a New Case of the Anaplastic Variant

Review Article: Spermatocytic Seminoma: Review of the Literature and Description of a New Case of the Anaplastic Variant

A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis

Das spermatozytäre Seminom

Contact Info

Product

Resources

About